Business description: GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

Number of employees: 3,103

Sales by Activity: GlaxoSmithKline Pharmaceuticals Limited

Fiscal Period: March 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR) 2026 (INR)

Pharmaceuticals

3.28TCr 3.25TCr 3.45TCr 3.75TCr 3.82TCr

Geographical breakdown of sales: GlaxoSmithKline Pharmaceuticals Limited

Fiscal Period: March 2022 (INR) 2023 (INR) 2024 (INR) 2025 (INR) 2026 (INR)

India

3.2TCr 3.19TCr 3.39TCr 3.7TCr 3.77TCr

Foreign

82Cr 64Cr 61Cr 50Cr 52Cr

Executive Committee: GlaxoSmithKline Pharmaceuticals Limited

Manager TitleAgeSince
Chief Executive Officer 56 01/12/2022
Director of Finance/CFO - 01/04/2026
Chief Tech/Sci/R&D Officer - 08/07/2024
Chief Tech/Sci/R&D Officer - 26/02/2024
Chief Administrative Officer - 01/12/2001

Composition of the Board of Directors: GlaxoSmithKline Pharmaceuticals Limited

Director TitleAgeSince
Chairman 73 01/04/2019
Director/Board Member 59 18/05/2020
Director/Board Member 67 16/05/2022
Director/Board Member 56 01/12/2022
Director/Board Member 65 26/03/2025
Director/Board Member 65 26/03/2025
Director/Board Member - 01/04/2026
Director/Board Member - 03/08/2026

Shareholders: GlaxoSmithKline Pharmaceuticals Limited

NameStocks%Valuation
75 %
12,70,54,524 75 % 4 075 M ₹
Life Insurance Corporation of India (Investment Portfolio)
1.082 %
18,33,698 1.082 % 59 M ₹
Nippon Life India Asset Management Ltd. (Invt Mgmt)
1.039 %
17,59,884 1.039 % 56 M ₹
SBI Funds Management Ltd. (Investment Management)
0.9706 %
16,44,261 0.9706 % 53 M ₹
Kotak Mahindra Asset Management Co. Ltd.
0.7353 %
12,45,595 0.7353 % 40 M ₹

Company details: GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Ltd.

GSK House

400030, Mumbai

+91 22 2495 9595

http://www.gsk-india.com
address GlaxoSmithKline Pharmaceuticals Limited(GLAXO)

Group companies: GlaxoSmithKline Pharmaceuticals Limited

NameCategory and Sector

Other Pharmaceuticals

Change 5-day change 1-year change 3-year change Capi.($)
Average
Weighted average by Cap.
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2,837.20INR
Average target price
3,081.00INR
Spread / Average Target
+8.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GLAXO Stock
  4. Company GlaxoSmithKline Pharmaceuticals Limited
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!